Neusignal Therapeutics Secures Additional Investment from Keio Innovation Initiative
Deal News | Jan 31, 2025 | Keio Innovation Initiative Inc
Keio Innovation Initiative Inc. (KII) has announced an additional investment in Neusignal Therapeutics, reflecting ongoing commitment and belief in the therapeutic potential and innovative capacities of the company. This funding aims to bolster Neusignal's research and development into cutting-edge therapeutics. As the primary venture capital arm associated with Japan's prestigious Keio University, KII follows a strategic investment approach targeting promising startups and innovative technologies, thereby actively contributing to their growth and success.
Sectors
- Biotechnology
- Venture Capital
Geography
- Japan – Keio Innovation Initiative is based in Japan, associated with Keio University, indicating a primary geographical focus on Japanese and potentially Asian markets.
Industry
- Biotechnology – Neusignal Therapeutics operates within the Biotechnology industry, focusing on innovative therapeutics research and development.
- Venture Capital – Keio Innovation Initiative is a venture capital firm investing in high-potential startups and innovative technologies.
Financials
- – The specific amount of additional investment made by Keio Innovation Initiative in Neusignal Therapeutics was not disclosed.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Keio Innovation Initiative Inc. | Investor | Company | A venture capital firm investing in startups and new technology ventures, particularly those associated with Keio University. |
| Neusignal Therapeutics | Target Company | Company | A biotechnology firm focused on the development of innovative therapeutics. |